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Background: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation
(CRT) is uncertain.
Methods: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal
adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy with concurrent capecitabine,
irinotecan and cetuximab. Resection was recommended 8 weeks later. The primary endpoint was histopathologically clear (R0)
resection margin. Pre-planned retrospective DNA pyrosequencing (PS) and next generation sequencing (NGS) of KRAS, NRAS,
PIK3CA and BRAF was performed on the pre-treatment biopsy and resected specimen.
Results: Eighty-two patients were recruited and 76 underwent surgery, with R0 resection in 67 (82%, 90%CI: 73–88%) (four patients
with clinical complete response declined surgery). Twenty–four patients (30%) had an excellent clinical or pathological response
(ECPR). Using NGS 24 (46%) of 52 matched biopsies/resections were discrepant: ten patients (19%) gained 13 new resection
mutations compared to biopsy (12 KRAS, one PIK3CA) and 18 (35%) lost 22 mutations (15 KRAS, 7 PIK3CA). Tumours only ever
testing RAS wild-type had significantly greater ECPR than tumours with either biopsy or resection RAS mutations (14/29 [48%] vs
10/51 [20%], P¼ 0.008), with a trend towards increased overall survival (HR 0.23, 95% CI 0.05–1.03, P¼ 0.055).
Conclusions: This regimen was feasible and the primary study endpoint was met. For the first time using pre-operative rectal CRT,
emergence of clinically important new resection mutations is described, likely reflecting intratumoural heterogeneity manifesting
either as treatment-driven selective clonal expansion or a geographical biopsy sampling miss.
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Preoperative chemoradiation (CRT) is a standard treatment in
locally advanced rectal cancer (Gerard et al, 2006; National
Institute for Health and Care Excellence, 2011; Schmoll et al, 2012;
Bossett et al, 2014) using a concurrent fluoropyrimidine
during 5 weeks of pelvic radiotherapy. To increase efficacy, adding
a second drug has been investigated. The combination of
capecitabine and irinotecan has been studied in phase II trials,
including by our own group (Gollins et al, 2011) with promising
response and survival.
The epidermal growth factor receptor (EGFR) is over-expressed
in approximately 60% of rectal cancers and associated with worse
prognosis (Giralt et al, 2005). Cetuximab is an anti-EGFR chimeric
monoclonal antibody demonstrating benefit when added to
chemotherapy for metastatic colorectal cancer (mCRC)
(Cunningham et al, 2004; Van Cutsem et al, 2009) but is
ineffective in the presence of RAS-activating mutations (Van
Cutsem et al, 2015).
Preclinical data indicated that cetuximab is a radiation sensitiser
and in head and neck cancer cetuximab combined with radio-
therapy improved median overall survival (OS) (Bonner et al,
2006). However, the benefit of cetuximab in addition to concurrent
single or doublet chemotherapy in rectal cancer CRT remains
uncertain. No phase III studies have been reported although in
early phase trials pathological complete response (pCR) rates
appear no greater than previously reported using CRT without
cetuximab, even when tumours were divided into KRAS wild-type
vs mutated (Clancy et al, 2013; Greenhalgh et al, 2016). However, a
randomised phase II trial (EXPERT-C) used 12 weeks of
oxaliplatin/capecitabine chemotherapy followed by CRT with
concurrent capecitabine, then surgery, then 12 further weeks of
oxaliplatin/capecitabine or the same regime plus weekly cetuximab.
In a subset of 90 KRAS/BRAF wild-type patients there was a
suggested improvement in overall response rate and survival with
cetuximab (Dewdney et al, 2012).
Our previous RICE study included 110 patients with similar
magnetic resonance imaging (MRI)-defined entry criteria to the
current study (EXCITE), examining CRT including irinotecan and
capecitabine without cetuximab (Gollins et al, 2011). EXCITE
assessed the toxicity, compliance and effectiveness of adding
cetuximab to the doublet of capecitabine/irinotecan during CRT.
RICE delivered capecitabine 7 days per week throughout CRT
whereas EXCITE gave capecitabine at similar dose 5 days per week
with radiotherapy, to avoid excessive toxicity. In EXCITE a pre-
planned retrospective analysis was carried out of EGFR pathway
mutations, using pyrosequencing (PS) and next generation
sequencing (NGS) of pre-treatment biopsy and post-resection
specimen, examining their influence on response and survival.
MATERIALS AND METHODS
Eligibility. EXCITE (EUDRACT 2007-006701-25) was a UK
multicentre, open-label, single arm phase II trial (full protocol available
at http://www.ctc.ucl.ac.uk/TrialDetails.aspx?Trial=76&TherA=7). Eli-
gible adult patients of World Health Organisation Performance
Status 0–1 had histopathologically confirmed rectal adenocarci-
noma with distal limit p12 cm from anal verge using rigid
sigmoidoscopy. Pelvic MRI-defined inclusion criteria comprised
mesorectal fascia (MRF) being threatened (tumour p1mm from
MRF), involved or breached, or low tumourso5 cm from the anal
verge. CT chest and abdomen excluded metastatic disease and
haematological and biochemical indices were satisfactory. Patients
were deemed fit to receive all study treatments.
Treatment. A CT-planned pelvic volume received megavoltage
radiotherapy at 45Gy in 25 daily fractions of 1.8 Gy treating 5 days
per week Monday–Friday. Patients received oral capecitabine
650mgm 2 b.d. on the days of radiotherapy only, cetuximab
400mgm 2 intravenously (i.v.) 1 week prior to radiotherapy then
250mgm 2 once-weekly during weeks 1–5 of radiotherapy and
irinotecan 60mgm 2 i.v. once-weekly during weeks 1–4 of
radiotherapy.
Surgery was recommended at 8 weeks following CRT. Post-
surgery, adjuvant chemotherapy was given at the treating
physician’s discretion. Patients were followed for 3 years post-
surgery to assess progression, survival and post-surgical and long-
term morbidity.
Assessments. The primary outcome measure was R0 resection
rate. Secondary outcomes were treatment compliance, grade 3
or 4 toxicity (NCI CTCAE version 3.0), post-operative morbidity,
pathological response, progression-free survival (PFS)
and OS.
R0 resection was defined as histologically clear margins
41mm, R1 microscopically involved margins p1mm and R2
macroscopically involved margins. Histological tumour regression
grade (TRG) was scored by the local pathologist as
0 (no regression), 1 (dominant tumour mass, o25% fibrosis),
2 (26–50% fibrosis), 3 (dominant fibrosis, 450% tumour
regression), 4 (‘microfoci’: scattered single tumour cells only) and
5 (pCR: no residual viable carcinoma on extensive examination of
the resected specimen), based on Ro¨del et al, 2005 with additional
TRG 4 based on our previous work, wherein we showed that
patients with either a pCR (TRG5) or microfoci (TRG4) following
CRT, had excellent long-term survival outcome compared to all
other patients achieving lesser degrees of downstaging (Gollins
et al, 2011).
Pre-treatment biopsy and surgical resection formalin-fixed
paraffin-embedded tumour tissue was collected and DNA
extracted at the Pathology and Tumour Biology laboratory,
University of Leeds. EGFR signalling pathway mutations were
analysed post-trial including KRAS codons 12, 13, 61, 146, NRAS
codons 12, 13, 61, PIK3CA codons 542, 545, 546, 1047, and the
BRAF V600E hotspot. Pyrosequencing (Richman et al, 2009) and
NGS (Supplementary Online Material) were performed by the
laboratory on the same specimen.
Mutated DNA was scored as present if it constituted at least 5%
of the total DNA analysed. The 5% cut-off was chosen after testing
a series of known dilutions to ascertain what could reliably be
detected without interference from false positives. The main
analysis examined KRAS and NRAS mutations in keeping with
subsequent evidence that both KRAS and NRAS mutations reduce
cetuximab effectiveness in mCRC (Van Cutsem et al, 2015),
reflected in the current product licence.
Statistical analysis. The primary endpoint of R0 resection rate
with single agent fluropyrimidine CRT was estimated at 55% and
adding irinotecan and cetuximab were expected to increase this to
at least 75%. Using a Fleming’s design with 80% power and one-
sided 5% level test of statistical significance, 35 patients would be
required. The initial recruitment target was therefore 40 patients,
allowing for drop-outs. As recruitment commenced in April 2009,
evidence emerged in the first line metastatic CRYSTAL trial (also
published in April 2009), suggesting that cetuximab was beneficial
in KRAS wild-type but not KRAS-mutated tumours (Van Cutsem
et al, 2009). However, it was unknown whether this would apply
using cetuximab concurrently with CRT. The sample size was
increased to 80 patients to give a 97% chance of at least 40 KRAS
wild-type tumours for R0 resection rate analysis, as mutated KRAS
was expected in 35–40% of colorectal adenocarcinomas. The
protocol-specified, pre-planned intention was to compare out-
comes for RAS wild-type vs mutant patients. This biomarker
analysis was exploratory, to assess the association with resection
and regression status and time to event endpoints.
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Data were analysed with the Stata SE 14 statistical package
according to intention to treat. Toxicity analyses were conducted
only in those patients who commenced treatment and the surgical
complications analysis only in those who had surgery.
Proportions were compared using chi-square tests (Fishers
Exact Test where appropriate). Kaplan–Meier censored survival
curves were used to present survival data with log-rank P-values.
Survival was calculated from the date of trial registration. PFS was
the time to the first event of local pelvic recurrence,
distant metastases, or death, and OS to death. Hazard ratios
(HR) were derived from Cox regression analysis. Pearson _X2 test
of independence to two-sided significance was used
where indicated.
The trial was approved by National Research Ethics Service
Committee: South Central–Oxford B (08/H0605/6), the Medicines
and Healthcare products Regulatory Agency (Clinical Trial
Authorisation number 20363/0228/001-0001), and by each
participating NHS Trust’s Research and Development department.
Informed consent was obtained from all patients.
RESULTS
Patients were recruited between April 2009 and October 2011 from
nine UK radiotherapy centres. Pre-treatment characteristics are
shown in Table 1, confirming locally advanced cancers, with 39
(48%) involving or breaching the MRF and the remainder margin-
threatened.
One poor-performance status patient did not start treatment.
Another received the initial cetuximab dose only and was then
withdrawn from the trial by the treating clinician, who considered
the radiotherapy treatment volume too large. As the primary
endpoint was histologically determined post-surgery, they were
replaced with two additional patients. Intention-to-treat analysis
included all 82 patients where appropriate.
Most patients received the full dose of radiotherapy (76 patients,
93%), irinotecan (56 patients, 68%) and cetuximab (60 patients,
73%) but only 39 (48%) received the full capecitabine dose
(Supplementary Online Material Table 1).
The commonest serious adverse events during CRT were grade
3 diarrhoea, acneiform rash and fatigue (Table 2). Five of six non-
haematological grade 4 adverse events were thromboembolic.
There were no treatment-related deaths prior to surgery.
Table 1. Baseline characteristics of patients in EXCITE
Baseline characteristics
Number of
patients (%)
Gender
Female 21 (26%)
Male 61 (74%)
Age at registration (years)
Median (range) 62 (26–79) [n¼82]
WHO performance status
0 62 (76%)
1 20 (24%)
Defunctioning stoma
Ileostomy 3 (4%)
Colostomy 4 (5%)
None 75 (91%)
Distance of distal end of tumour from anal verge using rigid
sigmoidoscopy (mm)a
Median (range) 50 (0–130) [n¼63]
Distance of distal end of tumour from anal verge using MRI (mm)a
Median (range) 50 (0–120) [n¼78]
Maximum superior-inferior tumour dimension (mm)
Median (range) 51 (5–110) [n¼76]
Maximum tumour diameter in a plane perpendicular to the
longitudinal central axis of the rectum (mm)
Median (range) 28 (10–100) [n¼55]
Not measurable [n¼25]
Missing [n¼ 2]
mrT-stage
T2 6 (7%)
T3 67 (82%)
T4 9 (11%)
mrN-stage
N0 14 (17%)
N1 42 (51%)
N2 26 (32%)
M-stage
M0 82 (100%)
Mesorectal edge on MRI scan
Potentially involved (p 1mm gap) 43 (52%)
Involved, not breached 22 (27%)
Breached 17 (21%)
Total 82 (100%)
Abbreviation: MRI¼magnetic resonance imaging.
aAll 82 patients had a measurement for distance of distal end of tumour from anal verge
using either rigid sigmoidoscopy or MRI.
Table 2. Grade 3–4 adverse events occurring during and up
to 4 weeks following completion of CRT (based on 81
patients that had some treatment)
Grade 3 Grade 4
No. of patients
(%)
No. of patients
(%)
Haematological adverse events
Anaemia 1 (1%) 1 (1%)
Leucopoenia 5 (6%) 1 (1%)
Thrombocytopenia 0 (0%) 1 (1%)
Neutropenia 4 (5%) 1 (1%)
Febrile neutropenia 1 (1%) 1 (1%)
Any haematological AE 10 (12%) 4 (5%)
Non-haematological adverse events
Diarrhoea 20 (25%) 0 (0%)
Acneiform rash 7 (9%) 0 (0%)
Fatigue 6 (8%) 0 (0%)
Dehydration 1 (1%) 0 (0%)
Pyrexia/Fever 1 (1%) 0 (0%)
Headache 1 (1%) 0 (0%)
Insomnia 1 (1%) 0 (0%)
Taste disturbance 1 (1%) 0 (0%)
Nausea 1 (1%) 0 (0%)
Vomiting 1 (1%) 0 (0%)
Urticaria 1 (1%) 0 (0%)
Other rash/skin reactionsa 7 (9%) 0 (0%)
Anal/rectal/bowel
complicationsb
6 (7%) 0 (0%)
Thrombotic eventc 1 (1%) 5 (6%)
Otherd 4 (5%) 1 (1%)
Any non-haematological adverse
event
36 (44%) 6 (7%)
Any adverse event 38 (47%) 10 (12%)
Abbreviations: AE¼ adverse event; CRT¼ chemoradiation.
aSkin related toxicity (2); rash (1); radiotherapy skin reaction (1); papular rash (1); shingles (1);
perineal desquamation (1).
bRectal pain (1); bowel obstruction (1); tenesmus (1); sore anal verge (1); pain passing stools/
rectal pain (1); perianal abscess (1).
cGrade 3: deep vein thrombosis (1). Grade 4: pulmonary embolism (3); thrombosis/
embolism (2).
dGrade 3: pulmonary infection(1); vasovagal attack(1); urinary tract problems (1); dry cracked
heels (1). Grade 4: urinary tract infection (1).
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Of the 80 patients commencing radiotherapy, 76 underwent
surgery, a median of 72 days (inter-quartile range (IQR) 62–94.5
days) post CRT completion with half undergoing an abdomino-
perineal excision (Supplementary Online Material Table 2).
Contrary to protocol, four patients with an endoscopically- and
MRI-confirmed complete clinical response (cCR) declined surgery
and were managed with a ‘watch-and-wait’ deferral of surgery
strategy off-trial. One postoperative death occurred within
30 days of surgery from bowel obstruction (Supplementary
Online Material Table 2).
Post-surgery, 54 patients (71%) received adjuvant chemother-
apy, 23 using a fluoropyrimidine (fluorouracil or capecitabine), 28
a fluoropyrimidine/oxaliplatin combination and 3 other.
A negative (R0) resection margin was achieved in 67 out of 82
patients: (82%, 90% CI: 73–88%), thereby meeting the primary
endpoint (lower 90% CI bound excluded 55%). A pCR (ypT0ypN0;
TRG 5) was found in 14 patients (17%) and near-complete
(microfoci; TRG 4) in 6 (7%) (Table 3).
We previously showed that rectal CRT patients achieving TRG
4–5 had superior survival to other patients (Gollins et al, 2011).
Management of four EXCITE patients with cCR by ‘watch-and-
wait’ was unexpected but they were included with resected patients
with TRG 4–5 for survival analysis; therefore, 24 of 80 patients who
commenced radiotherapy (30%) had an excellent clinical or
pathological response (ECPR).
The median follow-up was 37.4 months (IQR: 26.8–38.9
months). One patient developed local pelvic recurrence only, 15
distant metastases only and four both local and distant relapse.
Fifteen patients died and 26 had a PFS event. The four cCR
patients managed conservatively remained disease-free at 24, 39, 42
and 42 months. Thirty-six-month PFS for all 82 recruited patients
was 67% (95% CI:55–76%) and OS 80% (95% CI:69–87%).
Twenty-four of the 56 (43%) non-ECPR patients either
progressed or died compared to 2 of 24 (8%) with ECPR. The
36-month PFS for non-ECPR patients was 54% (95% CI: 39–66%)
and for ECPR 95% (95% CI: 74–99%) and OS 73% (95% CI: 58–
83%) vs 95% (95% CI: 72–99%) (Supplementary Online Material
Figure 1a and b).
EGFR pathway mutation status. Mutation status was retro-
spectively determined on biopsy samples from 78 patients and
resection specimens from 54, with 52 matched biopsy/resection
samples (Table 4). Resection mutation status could not be
determined in the 24 patients with ECPR because of no or very
little viable residual cancer.
Biopsy samples. Using PS, 45 (58%) of 78 biopsy samples had at
least one EGFR pathway mutation (52 mutations total), the
majority in KRAS codon 12 (Table 4). next generation sequencing
was more sensitive, identifying a further 21 mutations, the majority
in KRAS, all but one at a mutational percentage of 5–10% of the
total DNA present. By PS 37 (47%) and by NGS 44 (56%) of
biopsies were RAS (KRAS or NRAS) mutated.
By NGS 33 of 78 biopsy samples had a single, 12 a double, 4 a
triple and one a quadruple mutation (Supplementary Online
Material Table 3).
Resection samples. Using PS, 32 (59%) of 54 resection samples
had at least one EGFR mutation (35 mutations total), with an
additional 8 identified by NGS (Table 4). One PS mutation was not
confirmed with NGS. By PS/NGS, 33 resections (61%) were RAS
mutated. Twenty-six resections had a single, 7 a double and one a
triple mutation (Supplementary Online Material Table 3).
Matched biopsy/resection samples. In the 52 patients with
matched biopsy/resection specimens, 24 patients (46%) showed a
discrepancy between biopsy and resection (Table 5).
Ten patients (19%) gained 13 new resection mutations
compared to biopsy (10 KRAS 12, two KRAS 146 and one
PIK3CA). Nine patients gained at least one new RAS mutation and
five of these changed their overall RAS mutation status from biopsy
wild-type to resection mutated. Most new KRAS mutations (9 of
12) were present above 20% of the total DNA analysed.
Eighteen patients (35%) lost 22 mutations between biopsy and
resection (three KRAS 12, six KRAS 13, six KRAS 146, seven
PIK3CA). In the 14 patients solely losing mutations, five could be
detected at o5% in the resection specimen (KRAS 13 at 1% in
three patients and 4% in one and KRAS 146 at 2% in one).
Four of the above patients both lost and gained mutations.
The relationship between RAS mutation status and histological
response and survival. RAS mutation status was not related to R0
resection rate (Table 6). The difference in ECPR rate between
biopsy RAS mutated vs biopsy wild-type tumours was not
significant (23% vs 41% respectively, P¼ 0.090). However, there
was evidence that the new resection RAS mutations were clinically
important, in that patients who were ‘anytime’ RAS mutated in
either biopsy or resection had a lower ECPR rate (10/51: 20%)
Table 3. Histology of resected cancersa
Confirmed resection status Number (%)
R0 67 (82%)
R1 8 (10%)
R2 1 (1%)
Did not have surgery 6 (7%)
Tumour regression grade Number (%)
Grade 0 10 (12%)
Grade 1 11 (13%)
Grade 2 18 (22%)
Grade 3 17 (21%)
Grade 4 6 (7%)
Grade 5: pCR 14 (17%)
Did not have surgery 6 (7%)
T stage Number (%)
ypT0 14 (17%)
ypT1 1 (1%)
ypT2 17 (21%)
ypT3 40 (49%)
ypT4 3 (4%)
ypTx 1 (1%)
Did not have surgery 6 (7%)
N stage Number (%)
ypN0 52 (63%)
ypN1 15 (18%)
ypN2 9 (11%)
Did not have surgery 6 (7%)
T stage of resected specimen compared to
pre-treatment MRI scan Number (%)
Downstaged 37 (49%)
Unchanged 33 (44%)
Upstaged 5 (7%)
Total 75 (100%)
N stage of resected specimen compared to
pre-treatment MRI scan Number (%)
N1-2 downstaged 50 (78%)
N1-2 unchanged 12 (19%)
N1-2 upstaged 2 (3%)
Total 64 (100%)
N0 unchanged 9 (75%)
N0 upstaged 3 (25%)
Total 12 (100%)
Abbreviations: CRT¼ chemoradiation; MRI¼magnetic resonance imaging.
a82 patients were recruited to EXCITE in total and six patients did not have surgery because
two patients did not commence CRT and in 4 patients a ‘wait and watch’ approach was
adopted by the treating team because of a complete clinical response to CRT.
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Table 4. Mutations detected in biopsy and resection samples by PS and NGS
Mutation
Absolute
number of
mutations
detected by
PS Detail
Absolute number
of additional
mutations
detected by NGS
Detail (percentage
mutated DNA)
Biopsy (78 samples total)
KRAS 12 27
2  c.34G4A
1  c.34G4T
12  c.35G4A
2  c.35G4C
10  c.35G4T
5
1  c.34G4C (5%)
2  c.35G4A (6%, 8%)
2  c.35G4T (5%, 6%)
KRAS 13 3 3  c.38G4A 6 6  c.38G4A
(5%, 5%, 7%, 7%, 8%, 12%)
KRAS 61 0 — 0 —
KRAS 146 5 5 c.436G4A 4 4 c.436G4A (5%, 5%,
6%, 9%)
NRAS 12/13 2 c.35G4A
c.37G4C
0 —
NRAS 61 1 c.181C4A 0 —
BRAF 3 NA 0 —
PIK 542 5 5  c.1624G4A 1 1  c.1624G4A (5%)
PIK 545/546 5 3  c.1633G4A
1  c.1636C4A
1  c.1637A4C
3 2  c.1633G4A (5%, 10%)
1  c.1636C4A (5%)
PIK 1047 1 c.3140A4G 2 c.3139C4T (6%)
c.3140A4G (7%)
Total 52 21
Number of patients with RAS (KRAS or NRAS) mutation by PS 37 (47%)
Number of patients with RAS (KRAS or NRAS) mutation
by PS or NGS 44 (56%)
Number of patients with EGFR pathway mutation (KRAS, NRAS,
BRAF or PIK3CA) by PS 45 (58%)
Number of patients with EGFR pathway mutation (KRAS, NRAS,
BRAF or PIK3CA) by PS or NGS 50 (64%)
Resection (54 samples total)
KRAS 12 24
1  c.34G4A
2  c.34G4T
13  c.35G4A
1  c.35G4C
7  c.35G4T
3
2  c.34G4C (14%, 25%)
c.35G4C (7%)
KRAS 13 3 3  c.38G4A 0 —
KRAS 61 0 — 0 —
KRAS 146 2 2 c.436G4A 3 3 c.436G4A
(5%, 5%, 33%)a
NRAS 12/13 1 c.37G4C 0 —
NRAS 61 1 c.181C4A 0 —
BRAF 0 — 0 —
PIK 542 3 3  c.1624G4A 1 c.1624G4A (5%)
PIK 545/546 0 — 1 c.1633G4A (10%)
PIK 1047 1 c.3140A4G 0 —
Total 35 8
Number of patients with RAS (KRAS or NRAS) mutation by PS 31 (57%)
Number of patients with RAS (KRAS or NRAS) mutation by PS
or NGS 33 (61%)
Number of patients with EGFR pathway mutation (KRAS, NRAS,
BRAF or PIK3CA) by PS 32 (59%)
Number of patients with EGFR pathway mutation (KRAS, NRAS,
BRAF or PIK3CA) by PS or NGS 33 (61%)
Abbreviations: NA¼not applicable; NGS¼ next generation sequencing; PS¼pyrosequencing.
aOne sample that was resection KRAS 146 mutated on PS was non-mutated on NGS.
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compared to those who only ever tested RAS wild-type (14/29:
48%, P¼ 0.008).
There was some evidence of an improvement in PFS (HR 0.44
(95% CI: 0.18–1.10), P¼ 0.079) and OS (HR 0.23 (95% CI: 0.05–
1.03), P¼ 0.055) for wild-type compared to anytime-mutated
cancers (Figure 1A and B, Table 6), although this did not reach
statistical significance at the 5% level.
DISCUSSION
The regimen investigated was feasible, with acceptable rates of
treatment-related toxicity. EXCITE met its primary R0 resection
rate end point, although this was not improved compared to our
previous study (RICE) using concurrent irinotecan and capecita-
bine without cetuximab (82% vs 89% respectively) (Gollins et al,
2011). Likewise the EXCITE overall pCR (TRG 5) rate was similar
(EXCITE 14/82: 17% vs RICE 24/110: 22%), as was 3-year PFS
(EXCITE 67% and RICE 64%). In this respect our study was
similar to other early phase trials using concurrent cetuximab,
which have broadly failed to demonstrate an increase in pCR rate
compared to historical series using chemotherapy alone (Clancy
et al, 2013 and Greenhalgh et al, 2016).
Despite delivery of capecitabine at 650mgm 2 b.d. 5 days per
week compared to 7 in RICE, less than half our patients received
the full capecitabine dose. Two previous studies have examined
capecitabine/irinotecan/cetuximab concurrent with CRT (Erben
et al, 2011; Kim et al, 2013). One of these reported high compliance
with a lower capecitabine dose of 400–500mgm 2 (Erben et al,
2011) although this dose is significantly lower than when using
capecitabine alone (typically 825mgm 2). Theoretically such
lower achievable dose intensity may be due to increased toxicity
from the addition of cetuximab, as suggested for other tumour sites
(Crosby et al, 2013). In the current study capecitabine dose
reductions were protocol-driven. In the presence of grade 2
diarrhoea (the most common toxicity), capecitabine dose was to be
reduced to 75% ‘if no response to loperamide’. No time course over
which to make this assessment was recommended in the protocol,
however, which may have led to an increased tendency for
capecitabine dose reduction compared to irinotecan, where the
protocol stated that irinotecan dose was only to be lowered if there
was grade 3 toxicity.
Five patients in EXCITE experienced grade 4 thromboembo-
lism, which is greater than RICE (0%). The reason for this
difference is unclear although in no patient did this cause death or
compromise surgery. The two previous studies examining the
Table 5. Mutation data for the 52 matched samples using mutations identified on either PS or NGS
Pre-treatment biopsy mutation details
Post-resection specimen
mutation details Note/description
Biopsy and resection both non-mutated (n¼12)
NA NA NA
Biopsy and resection have matching mutations (n¼16)
KRAS 12 KRAS 12  10 patients
KRAS 146 KRAS 146  3 patients
NRAS 12/13 NRAS 12/13 1 patient
PIK 542 PIK 542  1 patient
KRAS 13, PIK 542 KRAS 13, PIK 542  1 patient
Discrepant results between biopsy and resection
EGFR pathway mutation gain between biopsy
and resection (n¼6)
No mutation KRAS 12 (25%)a No mutation to one mutation
No mutation KRAS 12 (27%) No mutation to one mutation
No mutation KRAS 12 (31%) No mutation to one mutation
No mutation KRAS 12 (13%), KRAS 146 (5%) No mutation to two mutations
No mutation KRAS 12 (14%); KRAS 12 (24%),
KRAS 146 (33%)
No mutation to three mutations
KRAS 12 (15%) KRAS 12 (18%), PIK 542 (24%) One mutation to two mutations
EGFR pathway mutation loss between biopsy
and resection (n¼14)
KRAS 12 (27%) No mutation One mutation to no mutation
KRAS 13 (12%) No mutation One mutation to no mutation
KRAS13 (41%) No mutation One mutation to no mutation
KRAS 12 (6%) No mutation One mutation to no mutation
KRAS 13 (27%) No mutation One mutation to no mutation
PIK 546 (5%) No mutation One mutation to no mutation
KRAS 146 (23%) No mutation One mutation to no mutation
KRAS 146 (5%), PIK 1047 (7%) No mutation Two mutations to no mutation
KRAS 12 (33%), KRAS 13 (5%) KRAS 12 (43%) Two mutations to one mutation
KRAS 12 (36%), PIK 542 (27%) KRAS 12 (38%) Two mutations to one mutation
KRAS 13 (41%), PIK 545 (40%) KRAS 13 (25%) Two mutations to one mutation
KRAS 12 (26%), KRAS 13 (7%) KRAS12 (31%) Two mutations to one mutation
KRAS 146 (6%), NRAS 61 (17%) NRAS 61 (27%) Two mutations to one mutation
KRAS 12 (9%), KRAS 13 (5%), PIK 545 (10%) KRAS 12 (14%), PIK 545 (10%) Three mutations to two mutations
EGFR pathway mutation loss and gain between
biopsy and resection (n¼4)
KRAS 12 c.35G4A (29%) KRAS12 c.34G4T (40%) One mutation to non-mutated plus gained one new mutation
KRAS 146 (33%), PIK 545 (37%) KRAS 12 (24%) Two mutations to non-mutated plus gained one new mutation
KRAS 146 (9%), PIK 542 (5%), PIK545 (5%) KRAS 12 (51%), PIK 542 (5%) Three mutations to one mutation plus gained one new mutation
KRAS 146 (5%), PIK 1047 (6%), PIK1047 (29%) KRAS 12 (34%), PIK 1047 (19%) Three mutations to one mutation plus gained one new mutation
Abbreviations: EGFR¼ epidermal growth factor receptor; NA¼ not applicable; NGS¼ next generation sequencing; PS¼pyrosequencing.
aThe number in brackets is the amount of mutated DNA as a percentage of the total DNA present.
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combination of irinotecan/capecitabine/cetuximab did not record
any thromboembolism associated with the regimen (Erben et al,
2011; Kim et al, 2013).
Unique features of the current study firstly included access to
the full set of biopsy and resection specimens for analysis of
mutational status. Secondly, in contrast to previously reported
studies we used the sensitive methodology of NGS for mutation
analysis. Thirdly, we studied an MRI-defined group of locally
advanced cancers whose mutational burden may be greater than
earlier stage disease.
In a substantial proportion of patients (46%) we found a
discrepancy in EGFR pathway mutations (mainly in KRAS)
comparing rectal cancer tissue pre- and post-CRT, which to our
knowledge has not previously been described. Even using NGS, only
one of the 12 new resection KRAS mutations could be detected at
o5% in the corresponding original biopsy (KRAS 12 at 1%).
In the 9 patients in which emergent new RAS mutations were
identified in the resected specimen, these appeared to be clinically
important in being associated with worse response and survival. Our
findings agree with previous reports in this context in that if solely
biopsy RAS mutations are considered, we did not find a statistically
significant decrease in EPCR rate compared to wild-type. However,
when the resection mutation status was additionally taken into
account (‘anytime’ mutated vs wild type), the difference in response
was significantly increased for wild-type, with a trend towards
improved survival. The implication is that clinically important low-
level RAS mutations in the pre-treatment biopsy, that contribute to
reduced response, are not identifiable with current biopsy and
sequencing techniques, even as sensitive as NGS, representing a
potential challenge to personalised medicine.
Possible explanations for emergence of new mutations in the
resection are either the treatment-driven selection and expansion
of initially undetectable low-level clones, biopsies which geogra-
phically missed the particular region of the tumour containing a
mutation, or both. Our findings thus provide evidence for
intratumoural clonal heterogeneity (ICH) in rectal cancer, which
lies at the root of either explanation. In the current study we found
additional evidence for ICH with a KRAS mutation being found
concurrent with another KRAS or NRAS or BRAF mutation in
eight biopsies, which is unusual (De Rook et al, 2010).
Disappearance of mutations in the current study could be
related to CRT response. Following macrodissection there was
sufficient neoplastic cell content (mean 25%) in the 14 resected
Table 6. Summary of the influence of RAS status (assessed by NGS) on histology and survival
Biopsy N¼78 Either biopsy or resection N¼80
RAS wild-type
N¼34
RAS mutated
N¼44 P-valuea
RAS wild-type
N¼29
RAS mutated
N¼51 P-valuea
R0 25 (74%) 39 (89%) 22 (76%) 44 (88%)
R1-2b 6 (18%) 3 (7%) 0.16 4 (14%) 5 (10%) 0.71
Did not have surgeryc 3 (9%) 2 (5%) 3 (10%) 2 (2%)
ECPRd 14 (41%) 10 (23%) 14 (48%) 10 (20%)
Non-ECPR 20 (59%) 33 (75%) 0.090 15 (52%) 40 (78%) 0.008
Did not have surgery and no CCRe 0 (0%) 1 (2%) 0 (0%) 1 (2%)
Progression-free survival HR 0.53
(95% CI: 0.23 to 1.22)
0.137 HR 0.44
(95% CI: 0.18 to 1.10)
0.079
Overall survival HR: 0.32
(95% CI: 0.09 to 1.14)
0.079 HR: 0.23
(95% CI: 0.05 to 1.03)
0.055
Abbreviations: CCR=clinical complete response; CI=confidence interval; ECPR¼ excellent clinical or pathological response; HR¼hazard ratio; NGS¼next generation sequencing; OS¼overall
survival; PFS¼progression-free survival.
aWhen appropriate, Chi-square tests or Fisher’s exact test used for resection and ECPR status; log rank test used for PFS and OS.
bOne patient was considered an R2 resection.
cPatients who did not have surgery were not included in the Fisher’s exact test.
dFour patients with ECPR had complete clinical responses and were managed expectantly without resection: three were biopsy KRAS/NRAS non-mutated and one was biopsy mutated.
eThe RAS mutated patient who did not have surgery and did not have complete clinical response was not included in the Chi-square test analysis.
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Figure 1. Relationship between RAS mutation status and progression-
free and overall survival. (A) progression-free survival and (B) overall
survival in patients who were RAS mutated in either pre-treatment
biopsy or resected specimen (‘anytime mutant’) versus patients whose
specimens only ever tested RAS wild-type.
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tumours solely losing mutations, to have detected the original
biopsy mutations if present.
There is increasing awareness of ICH in colorectal cancer,
with potential clinical relevance. A study sampling multiple locations
from the same colorectal tumour showed that using
PS, 7 of 69 primary tumours (10%) demonstrated ICH (Richman
et al, 2011) and genomic profiles of primary tumours and metastases
are not always concordant (Vogelstein et al, 2013). On analysing 349
individual lymph glands from 15 colorectal tumours, uniformly high
ICH and subclone mixing was demonstrated in both primary
tumour and lymph nodes, and it was proposed that most detectable
ICH results from early subclonal alterations (Sottoriva et al, 2015).
During treatment with anti-EGFR monoclonal antibodies, emer-
gence of RAS and other mutations can be identified in circulating
tumour DNA (ctDNA) before clinically apparent disease progression
(Diaz et al 2012; Siravegna et al 2015). Using RNA transcriptomic
analysis, it has recently been shown that patients can be
simultaneously classified into multiple diagnostically relevant
subgroups based purely on the tumoural region analysed (Dunne
et al, 2016).
In the current study it does seem likely that at least some of the
emergent resection mutations that were not identified in pre-
treatment biopsy arose because of treatment-driven clonal
expansion, because most newly identified KRAS mutations (9 of
12) were present above 20% of the total DNA analysed. By
definition, these mutations have arisen within an approximate 3-
month period from biopsy to resection, implying that rapid clonal
selection may have occurred, possibly accelerated by the well-
known phenomenon of radiotherapy-induced accelerated repopu-
lation (Willers and Held, 2006).
A limitation of the current study is the relatively small sample
size and non-randomised nature, meaning that these observations
remain hypothesis-generating and no conclusions can be drawn for
use in routine clinical practice. It is not known if a similar
emergence of resection RASmutations would occur if patients were
treated with CRT containing irinotecan and capecitabine alone
without cetuximab. We are currently examining our previous RICE
trial from this point of view.
In terms of future research, there are currently no recom-
mended national standards for pre-treatment rectal biopsy in
routine clinical practice. There is a need to define biopsy standards
in terms of number of biopsies, volume and location, in order to
increase the pre-treatment sensitivity of identifying clinically
relevant mutations if preset. The use of NGS will also maximise
sensitivity for identifying such mutations. In addition, sequential
biopsy of the primary tumour during treatment may allow more
early definition of emerging mutations, which could influence
treatment approach. The use of liquid biopsies taken at baseline
and at intervals during treatment may give information on such
emergent mutational changes, without the need for repeat tissue
biopsy (Spindler et al, 2015).
In summary, the regimen studied was feasible and met its
primary R0 resection endpoint. Using the sensitive technology of
NGS, comparing biopsy with resection, we describe for the first
time substantial loss and gain of EGFR pathway mutations (mainly
KRAS) in locally advanced rectal cancer undergoing pre-operative
CRT. Appearance of new, initially undetectable RAS mutations,
was related to significantly decreased response and a trend to
inferior survival in tumours that were RAS mutated in either
biopsy or resection compared to those only ever testing wild-type.
Failure to detect such clinically important emergent resection
mutations in pre-treatment biopsies may be related to a lack of
influence of RAS mutation status on response in previous reports.
This phenomenon is likely to be due to ICH manifesting as either
treatment-driven selection of mutated clones or a biopsy
geographical miss, thereby presenting a challenge to personalised
medicine. Our findings highlight an urgent need to define a
minimum standard for adequate pre-treatment biopsies in routine
clinical practice.
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